Ensysce Biosciences has acquired Cy Biopharma for an undisclosed amount, a transaction that consolidates two clinical-stage biotechnology firms focused on pain management and rare disease therapeutics. The deal brings Cy Biopharma’s development pipeline and executive team under Ensysce’s operational umbrella, effective immediately.
Cy Biopharma, led by Chief Executive Officer James Morrison, has been developing novel solutions for chronic pain and rare conditions, with a stated mission of redefining pain medicine. Its clinical programs, overseen by Chief Medical Officer Prof. Richard Langford and Chief Finance Officer Dr. Roger Sawhney, will now be integrated into Ensysce’s broader research framework. Ensysce, which specializes in abuse-deterrent opioid technologies and precision pain treatments, gains access to Cy Biopharma’s early-stage assets and its leadership’s regulatory experience.
The acquisition is strategic for Ensysce in two respects. First, it expands the company’s portfolio beyond its current focus on abuse-deterrent formulations into rare disease indications, diversifying its revenue potential. Second, it adds clinical and financial expertise from Cy Biopharma’s senior team, which has navigated complex trial designs and funding structures in the pain space. Ensysce expects to leverage these capabilities to accelerate ongoing studies and reduce development timelines for combined programs.
For Cy Biopharma, the sale provides a path to scale its research without the burden of standalone fundraising, while its shareholders gain exposure to Ensysce’s larger platform. No changes to Cy Biopharma’s ongoing trial sites or patient enrollment have been announced, and the company’s contact for trial details remains active.
The combined entity will operate under Ensysce’s corporate structure, with Cy Biopharma’s pipeline folded into a unified development calendar. The immediate focus is on harmonizing clinical protocols and preparing regulatory filings for the most advanced assets. Whether the deal yields near-term milestones will depend on how smoothly the two teams integrate their respective trial data and manufacturing plans.